Cargando…
The PDGFRβ/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer
BACKGROUND: CDCP1, a transmembrane protein with tumor pro-metastatic activity, was recently identified as a prognostic marker in TNBC, the most aggressive breast cancer subtype still lacking an effective molecular targeted therapy. The mechanisms driving CDCP1 over-expression are not fully understoo...
Autores principales: | Forte, Luca, Turdo, Federica, Ghirelli, Cristina, Aiello, Piera, Casalini, Patrizia, Iorio, Marilena Valeria, D’Ippolito, Elvira, Gasparini, Patrizia, Agresti, Roberto, Belmonte, Beatrice, Sozzi, Gabriella, Sfondrini, Lucia, Tagliabue, Elda, Campiglio, Manuela, Bianchi, Francesca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5967041/ https://www.ncbi.nlm.nih.gov/pubmed/29792166 http://dx.doi.org/10.1186/s12885-018-4500-9 |
Ejemplares similares
-
CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers
por: Turdo, Federica, et al.
Publicado: (2016) -
Wound Healing Fluid Reflects the Inflammatory Nature and Aggressiveness of Breast Tumors
por: Agresti, Roberto, et al.
Publicado: (2019) -
MiR-205 as predictive biomarker and adjuvant therapeutic tool in combination with trastuzumab
por: Cataldo, Alessandra, et al.
Publicado: (2018) -
Decoding Immune Heterogeneity of Triple Negative Breast Cancer and Its Association with Systemic Inflammation
por: Romero-Cordoba, Sandra, et al.
Publicado: (2019) -
Extracellular Matrix Features Discriminate Aggressive HER2-Positive Breast Cancer Patients Who Benefit from Trastuzumab Treatment
por: Rybinska, Ilona, et al.
Publicado: (2020)